Edwin Liu
Concepts (356)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 65 | 2026 | 308 | 10.550 |
Why?
| | Autoantibodies | 49 | 2026 | 1497 | 3.090 |
Why?
| | Transglutaminases | 28 | 2025 | 159 | 2.960 |
Why?
| | Diet, Gluten-Free | 13 | 2026 | 56 | 2.040 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 173 | 1.860 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 463 | 1.520 |
Why?
| | Autoimmunity | 23 | 2024 | 924 | 1.470 |
Why?
| | GTP-Binding Proteins | 12 | 2025 | 153 | 1.370 |
Why?
| | Diabetes Mellitus, Type 1 | 47 | 2024 | 3842 | 1.330 |
Why?
| | Genetic Predisposition to Disease | 21 | 2024 | 2359 | 1.230 |
Why?
| | Peptide Fragments | 15 | 2008 | 698 | 1.210 |
Why?
| | Insulin | 24 | 2009 | 2501 | 1.180 |
Why?
| | Glutens | 10 | 2023 | 59 | 0.930 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 76 | 0.870 |
Why?
| | Islets of Langerhans | 17 | 2017 | 832 | 0.830 |
Why?
| | Rett Syndrome | 1 | 2024 | 41 | 0.820 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 220 | 0.730 |
Why?
| | Insulin Antibodies | 11 | 2013 | 103 | 0.720 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 216 | 0.720 |
Why?
| | Patient Compliance | 3 | 2026 | 585 | 0.720 |
Why?
| | Nutrition Therapy | 1 | 2020 | 36 | 0.630 |
Why?
| | Child | 46 | 2026 | 22537 | 0.620 |
Why?
| | Genetic Testing | 6 | 2015 | 478 | 0.600 |
Why?
| | Pyrrolidinones | 1 | 2019 | 29 | 0.600 |
Why?
| | Child, Preschool | 33 | 2026 | 11774 | 0.590 |
Why?
| | Mice, Inbred NOD | 22 | 2013 | 610 | 0.550 |
Why?
| | Nutritionists | 3 | 2026 | 24 | 0.520 |
Why?
| | Immunoglobulin A | 9 | 2025 | 214 | 0.510 |
Why?
| | Down Syndrome | 2 | 2023 | 534 | 0.510 |
Why?
| | Anticonvulsants | 1 | 2019 | 234 | 0.510 |
Why?
| | Mass Screening | 8 | 2024 | 1332 | 0.500 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 198 | 0.470 |
Why?
| | Intestinal Mucosa | 5 | 2026 | 676 | 0.450 |
Why?
| | Humans | 88 | 2026 | 144261 | 0.450 |
Why?
| | Infant | 27 | 2025 | 10022 | 0.440 |
Why?
| | Epilepsy | 1 | 2019 | 375 | 0.430 |
Why?
| | Anaphylaxis | 3 | 2004 | 102 | 0.410 |
Why?
| | Poly I-C | 4 | 2008 | 57 | 0.390 |
Why?
| | Adolescent | 26 | 2026 | 22281 | 0.390 |
Why?
| | Depression | 2 | 2022 | 1533 | 0.380 |
Why?
| | Caregivers | 1 | 2022 | 1047 | 0.380 |
Why?
| | Female | 59 | 2026 | 77976 | 0.380 |
Why?
| | Gliadin | 3 | 2018 | 13 | 0.370 |
Why?
| | Radioimmunoassay | 3 | 2016 | 165 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2024 | 2143 | 0.350 |
Why?
| | Prospective Studies | 21 | 2024 | 7970 | 0.340 |
Why?
| | Male | 50 | 2026 | 72035 | 0.340 |
Why?
| | Follow-Up Studies | 12 | 2024 | 5389 | 0.330 |
Why?
| | Jejunum | 1 | 2011 | 35 | 0.330 |
Why?
| | Telemedicine | 1 | 2020 | 940 | 0.330 |
Why?
| | Biopsy | 11 | 2025 | 1075 | 0.330 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 245 | 0.320 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.310 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1983 | 0.300 |
Why?
| | Quality of Life | 5 | 2024 | 3166 | 0.290 |
Why?
| | Risk Factors | 17 | 2024 | 10699 | 0.280 |
Why?
| | Luminescent Measurements | 2 | 2020 | 76 | 0.280 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 67 | 0.280 |
Why?
| | Dietary Proteins | 2 | 2019 | 136 | 0.280 |
Why?
| | Laboratories | 1 | 2009 | 109 | 0.270 |
Why?
| | Interferon-alpha | 2 | 2005 | 197 | 0.260 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.260 |
Why?
| | Mice | 32 | 2013 | 18329 | 0.250 |
Why?
| | Poly A-U | 1 | 2006 | 3 | 0.250 |
Why?
| | T-Lymphocytes | 7 | 2008 | 1982 | 0.240 |
Why?
| | Immune Tolerance | 4 | 2013 | 379 | 0.240 |
Why?
| | Europe | 6 | 2017 | 412 | 0.240 |
Why?
| | Serologic Tests | 4 | 2021 | 53 | 0.230 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2026 | 62 | 0.220 |
Why?
| | HLA Antigens | 5 | 2019 | 225 | 0.220 |
Why?
| | Time Factors | 10 | 2025 | 7155 | 0.220 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.220 |
Why?
| | Dyspepsia | 1 | 2024 | 10 | 0.220 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 2111 | 0.210 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 850 | 0.210 |
Why?
| | CD4 Antigens | 2 | 2003 | 139 | 0.210 |
Why?
| | Antibodies | 3 | 2014 | 401 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Gastrointestinal Agents | 1 | 2024 | 66 | 0.200 |
Why?
| | Genotype | 7 | 2019 | 1833 | 0.200 |
Why?
| | Autoantigens | 6 | 2009 | 429 | 0.200 |
Why?
| | Animals | 34 | 2015 | 38030 | 0.200 |
Why?
| | Iron | 1 | 2026 | 359 | 0.200 |
Why?
| | Abdominal Pain | 1 | 2024 | 146 | 0.190 |
Why?
| | Diet | 4 | 2019 | 1271 | 0.190 |
Why?
| | Peptides | 3 | 2018 | 995 | 0.190 |
Why?
| | Endosonography | 1 | 2024 | 157 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 668 | 0.190 |
Why?
| | Biomarkers | 7 | 2025 | 4254 | 0.190 |
Why?
| | Mice, Inbred BALB C | 8 | 2009 | 1253 | 0.180 |
Why?
| | Ileal Diseases | 1 | 2001 | 14 | 0.180 |
Why?
| | Seasons | 1 | 2024 | 556 | 0.180 |
Why?
| | Short Bowel Syndrome | 1 | 2001 | 27 | 0.170 |
Why?
| | Prevalence | 4 | 2026 | 2815 | 0.170 |
Why?
| | Catheterization | 2 | 2001 | 183 | 0.170 |
Why?
| | Colonic Diseases | 1 | 2001 | 34 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1646 | 0.170 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1322 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2013 | 2182 | 0.160 |
Why?
| | Dietetics | 1 | 2020 | 24 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 537 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2024 | 587 | 0.150 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 94 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 1128 | 0.150 |
Why?
| | Incidence | 5 | 2022 | 2870 | 0.150 |
Why?
| | Infant, Newborn | 8 | 2019 | 6424 | 0.150 |
Why?
| | Vaccines | 1 | 2004 | 389 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 82 | 0.150 |
Why?
| | Immunization | 4 | 2007 | 374 | 0.150 |
Why?
| | Probiotics | 1 | 2019 | 61 | 0.140 |
Why?
| | Risk | 3 | 2019 | 909 | 0.140 |
Why?
| | Duodenum | 3 | 2023 | 77 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5813 | 0.140 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 1092 | 0.140 |
Why?
| | Adoptive Transfer | 4 | 2008 | 198 | 0.140 |
Why?
| | Risk Assessment | 8 | 2020 | 3637 | 0.130 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 365 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2026 | 17009 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1519 | 0.130 |
Why?
| | Anxiety | 2 | 2022 | 1104 | 0.130 |
Why?
| | Parents | 2 | 2024 | 1401 | 0.120 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 15 | 0.120 |
Why?
| | United States | 9 | 2025 | 15876 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 48 | 0.120 |
Why?
| | Feces | 1 | 2019 | 513 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 175 | 0.120 |
Why?
| | Cesarean Section | 1 | 2018 | 224 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2016 | 63 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 79 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6021 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2020 | 777 | 0.110 |
Why?
| | Disease Models, Animal | 5 | 2006 | 4556 | 0.110 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 87 | 0.110 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3403 | 0.110 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 74 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2021 | 893 | 0.100 |
Why?
| | Case-Control Studies | 6 | 2019 | 3592 | 0.100 |
Why?
| | Homozygote | 1 | 2014 | 199 | 0.100 |
Why?
| | Weight Gain | 1 | 2017 | 556 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 427 | 0.100 |
Why?
| | ROC Curve | 3 | 2013 | 612 | 0.100 |
Why?
| | International Cooperation | 2 | 2016 | 197 | 0.100 |
Why?
| | Mice, Knockout | 8 | 2009 | 3119 | 0.100 |
Why?
| | Clonal Anergy | 1 | 2013 | 54 | 0.090 |
Why?
| | Child Development | 1 | 2017 | 484 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Mice, SCID | 4 | 2008 | 369 | 0.090 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 160 | 0.090 |
Why?
| | Cohort Studies | 6 | 2025 | 5935 | 0.090 |
Why?
| | Young Adult | 5 | 2024 | 13990 | 0.090 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 80 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 2154 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.090 |
Why?
| | Protein Precursors | 2 | 2003 | 136 | 0.090 |
Why?
| | Sweden | 3 | 2017 | 111 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1091 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 964 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 482 | 0.090 |
Why?
| | Breast Feeding | 1 | 2015 | 448 | 0.090 |
Why?
| | Colorado | 2 | 2024 | 4562 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1682 | 0.090 |
Why?
| | Heterozygote | 2 | 2016 | 315 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2024 | 11643 | 0.080 |
Why?
| | Adenoviridae | 2 | 2019 | 199 | 0.080 |
Why?
| | Proinsulin | 3 | 2008 | 51 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1906 | 0.080 |
Why?
| | Plant Proteins | 1 | 2011 | 112 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2021 | 315 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 681 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 33 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 917 | 0.080 |
Why?
| | Mice, Inbred C57BL | 8 | 2013 | 5988 | 0.080 |
Why?
| | Radioligand Assay | 1 | 2009 | 37 | 0.070 |
Why?
| | Prediabetic State | 3 | 2009 | 243 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1409 | 0.070 |
Why?
| | Bilirubin | 2 | 2008 | 97 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2008 | 25 | 0.070 |
Why?
| | Ammonia | 2 | 2008 | 65 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 31 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2917 | 0.070 |
Why?
| | Decision Support Techniques | 1 | 2013 | 454 | 0.070 |
Why?
| | Dietary Supplements | 2 | 2026 | 575 | 0.070 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 11 | 0.070 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 164 | 0.070 |
Why?
| | Spleen | 3 | 2007 | 508 | 0.070 |
Why?
| | Biopsy, Needle | 2 | 2011 | 183 | 0.070 |
Why?
| | Disease Progression | 6 | 2016 | 2840 | 0.070 |
Why?
| | Hyperglycemia | 2 | 2008 | 374 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 29 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 55 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 102 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2020 | 346 | 0.060 |
Why?
| | Self-Help Groups | 1 | 2007 | 37 | 0.060 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 202 | 0.060 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 12 | 0.060 |
Why?
| | Adult | 8 | 2023 | 40262 | 0.060 |
Why?
| | Blood Glucose | 3 | 2006 | 2312 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 784 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2006 | 124 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 299 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 294 | 0.060 |
Why?
| | Logistic Models | 3 | 2017 | 2104 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 41 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2026 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 166 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 1112 | 0.060 |
Why?
| | Age Factors | 3 | 2017 | 3313 | 0.060 |
Why?
| | Isoelectric Point | 1 | 2004 | 23 | 0.050 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 9 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 111 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2929 | 0.050 |
Why?
| | Survival Rate | 2 | 2007 | 2088 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 98 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 876 | 0.050 |
Why?
| | Pancreatitis, Chronic | 1 | 2024 | 62 | 0.050 |
Why?
| | Canada | 1 | 2025 | 428 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2005 | 178 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 331 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2024 | 180 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 266 | 0.050 |
Why?
| | Nerve Block | 1 | 2024 | 103 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 485 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 561 | 0.050 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 160 | 0.050 |
Why?
| | Enkephalins | 1 | 2002 | 21 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 6 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 31 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1487 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2603 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 38 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2002 | 43 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2004 | 901 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 364 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 65 | 0.040 |
Why?
| | Immunotherapy | 1 | 2007 | 652 | 0.040 |
Why?
| | Oligopeptides | 1 | 2003 | 268 | 0.040 |
Why?
| | Paracentesis | 1 | 2001 | 16 | 0.040 |
Why?
| | Gastroschisis | 1 | 2001 | 32 | 0.040 |
Why?
| | Ascites | 1 | 2001 | 49 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 157 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 730 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1487 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 4278 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 97 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1382 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 487 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 863 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1834 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 284 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 85 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 288 | 0.040 |
Why?
| | Colonoscopy | 1 | 2001 | 260 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 71 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1559 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1867 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5592 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2926 | 0.030 |
Why?
| | Metagenomics | 1 | 2019 | 181 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 121 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 483 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2020 | 281 | 0.030 |
Why?
| | Rotavirus | 1 | 2016 | 20 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 166 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 37 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 643 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 484 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 797 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 3157 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1705 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 778 | 0.030 |
Why?
| | China | 1 | 2016 | 269 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1739 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 264 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 179 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 511 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 191 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 129 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 99 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1422 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 674 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 83 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1964 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 481 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1715 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 301 | 0.020 |
Why?
| | Base Sequence | 2 | 2008 | 2187 | 0.020 |
Why?
| | Intestines | 1 | 2015 | 358 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 729 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1312 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 134 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 246 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 396 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 847 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 165 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2420 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2096 | 0.020 |
Why?
| | Species Specificity | 2 | 2004 | 574 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 415 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 535 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 774 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 60 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 397 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 380 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 13 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 7180 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 35 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 21 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 15 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 37 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 76 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1126 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2916 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2382 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 23 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 245 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 16 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 379 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 39 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 93 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 187 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 331 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 294 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4146 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 649 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 40 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 169 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2879 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 106 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 536 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 67 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 72 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2516 | 0.010 |
Why?
| | Plasma Volume | 1 | 2001 | 20 | 0.010 |
Why?
| | Punctures | 1 | 2001 | 40 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1812 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 555 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 229 | 0.010 |
Why?
| | Needles | 1 | 2001 | 62 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 112 | 0.010 |
Why?
| | Drainage | 1 | 2001 | 185 | 0.010 |
Why?
| | Safety | 1 | 2001 | 355 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 878 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 846 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3057 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 35762 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 4085 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|